A prospective class action lawsuit has been filed against Boehringer Ingelheim Pharmaceutical Inc., alleging the Big Pharma company made false and misleading statements regarding its Combivent Respimat asthma inhaler.

The 24-page federal lawsuit in Connecticut accuses the international company of conducting “an extensive, widespread, comprehensive and uniform nationwide marketing campaign” that misrepresented the dosage of its Combivent inhalers. It claims the company offered metered-dose inhalers that were supposed to provide a set number of constant puffs, but which fell far short.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]